B
Beverly L. Davidson
Researcher at Children's Hospital of Philadelphia
Publications - 410
Citations - 35019
Beverly L. Davidson is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Gene silencing & RNA interference. The author has an hindex of 94, co-authored 391 publications receiving 33041 citations. Previous affiliations of Beverly L. Davidson include United States Department of Veterans Affairs & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
P 1 Caco-2 cells as an in vitro model for adenoviral gene transfer to the gut epithelium
Elke Walter,Maria A. Croyle,Beverly L. Davidson,Blake J. Roessler,John M. Hilfinger,Gordon L. Amidon +5 more
Journal ArticleDOI
717. RNAi Therapy for Dominant Neurodegenerative Diseases
Haibin Xia,Qinwen Mao,Steven Eliason,Nathan Kiewiet,Jaime Critchfield,Inês Martins,Scott Q. Harper,Xiaohua He,Robert M. Kotin,Huda Y. Zoghbi,Harry T. Orr,Henry L. Paulson,Beverly L. Davidson +12 more
TL;DR: These data provide the first in vivo demonstration of efficacy of RNAi for dominant neurodegenerative disease therapy and directly compare transduced and untransduced lobules for ataxin-1 nuclear inclusions, Purkinje cell morphology, and the width of the cerebellar molecular layer.
Patent
Compounds and methods for detecting tripeptidyl protease I
TL;DR: In this paper, the enzyme tripeptidyl protease I (TPP-1) was detected using a combination of p-anisaldehyde and gly-L-Pro-L -Ser-1-anthraquinonylhydrazide.
Journal ArticleDOI
Synthesis of normal and variant human hypoxanthine-guanine phosphoribosyltransferase in Escherichia coli
TL;DR: By taking advantage of a T7 polymerase/promoter system, both normal and variant human hprt sequences in E. coli are expressed and the proteins synthesized are immunologically and enzymatically active, and are physically indistinguishable from the HPRT in B-lymphoblasts derived from normal and three H PRT-deficient subjects.
Patent
Gene transfer compositions, methods and uses for treating neurodegenerative diseases
TL;DR: In this article, the authors present methods of treating a lysosomal storage disorder in a mammal which method includes administering AAV particles encoding a polypeptide to the central nervous system of the mammal.